Department of Medicinal and Biological Chemistry

Paul W. Erhardt, Ph.D.

Dr. Erhardt photo

Distinguished University Professor
Director, Center for Drug Design and Development (CD3)

419.530.2167 Phone
Wolfe Hall 2206


B.A., Chemistry, 1969 University of Minnesota
Ph.D., Medicinal Chemistry, 1974 University of Minnesota
Post-doctoral Research Associate, 1974-1975 University of Texas at Austin

Synthetic medicinal agents; organic and peptidomimetic compounds; small-ring scaffold systems; nitrogen asymmetry and racemic inversion; 'metabophore' technologies. 

Research Interests

Our group is interested in three major areas. The first involves translating information about biochemical pathways into practical, small organic or peptidomimetic therapeutic agents. Today's explosion of biotechnology-related information has provided a plethora of such opportunities. As a result, it is possible to select problems which can be esthetically pleasing at the molecular level (e.g., those which may be amenable to approaches involving small, symmetrical scaffolds), as well as having the potential to make a major impact upon the health of man (e.g., choosing problems in a major disease category which has eluded adequate therapeutic intervention). One of our ongoing programs in this area involves pursuit of small-molecule versions of the new anticancer agent paclitaxel (1).

A second area of interest involves constructing appendant molecular systems which rely upon in vivo metabolic processes ('metabophores') to alter the properties of their parent drugs in a programmed manner so as to enhance the overall therapeutic profiles of the new composite molecules. This technology has numerous applications, but is particularly useful when combined with topical and critical care medications, as was done successfully in the design of the ultra-short-acting beta-adrenergic receptor blocking agent esmolol (2).

Finally, a third area of interest involves developing rational libraries of molecular probes which can be utilized to survey receptor topographies and to provide initial lead structures during the early phases of drug discovery.

AsDirector of the CD3 my involvement encompasses all aspects of pharmaceutical research and development, ranging from the design and synthesis of small-molecule therapeutics to the advanced clinical study of marketed drugs and diagnostic agents. In this capacity, the CD3 participates in a wide range of collaborative research activities throughout the University and its immediately surrounding medical research community.

Recent Publications

  1. Erhardt, P. and Y-L. Chou. Topographical model for the cAMP phosphodiesterase III active site. Life Sciences 49, 553, 1991.

  2. Shaw, K., P. Erhardt, A. Hagedorn, C. Pease, W. Ingebretsen and J. Wiggins. Cardiotonic agents 7. Prodrug derivatives of 4-ethyl-1,3-dihydro-5-[4-(2-methyl)-1H-imidazol-1-yl)benzoyl]-2H-imidazole-2-one. J. Med. Chem. 35, 1267, 1992.

  3. Erhardt, P. Endothelin structure and structure-activity relationships. In Endothelin, C. Rubanyi, Ed., Oxford University Press, London, 1992.

  4. Lampe, J., Y.-L. Chou, R. Hanna, S. DiMeo, P. Erhardt, A. Hagedorn III, W. Ingebretsen and E. Cantor. (Imidazolylphenyl)pyrrol-2-one Inhibitors of Cardiac cAMP Phosphodiesterase. J. Med. Chem. 36, 1041, 1993.

  5. Erhardt, P. Esmolol. In Chronicles of Drug Discovery. D. Lednicer, Ed. ACS Books, Washington, D.C., 1993

  6. Bihovsky, R., B. Levinson, R. Loewi, P. Erhardt and M. Polokoff. Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle. J. Med. Chem. 38, 2119-2129, 1995.

  7. Bihovsky, R., P. Erhardt, J. Lampe, R. Mohan and K. Shaw. Inhibitors of the conversion of big endothelin to endothelin. U.S. Patent 5 504 070, 1996.

  8. Erhardt, P. The Biochemical Mechanism of Paclitaxel: In Pursuit of a Microtubule Binding Site. The Taxane Journal 3: 36-42,1997.

  9. Erhardt, P. Chemotherapeutic Agents. Lecture 1. Am. J. Pharmaceut. Ed., 61, 192-196,1997.

  10. Hu, Z. and P. Erhardt. Utilization of a Benzoyl Migration to Effect an Expeditious Synthesis of the Paclitaxel Side Chain Org. Process Res. & Develop., 387-390,1997.

  11. Sarver J., R. Pryka, K. Alexander, L. Weinstein and P. Erhardt Stability of Magnesium Sulfate in 0.9% Sodium Chloride and Lactated Ringers Solutions. Int. J. Pharmaceutical Compd., 2, 385-388,1998.

  12. Erhardt, P. Drug Metabolism Data: Past and Present Status., Medicinal Chemistry Research 8: 7-8, 400-421,1998.

  13. Erhardt, P. Benzylamine-Related Chiral Auxiliary Synthetic Reagents.. U.S. Patent, 5,977,409,1999.

  14. J. Sarver, N. Peng, S. Lerdkanchanaporn, K. Oravecz-Wilson, K. Alexander and P. Erhardt. Analysis of Extemporaneous Alprostadil Formulations Intended for the Treatment of Erectile Dysfunction Int. J. Pharmaceutical Compd. 3:148-155,1999.

  15. Drug Metabolism Data: Past, Present and Future Considerations. P. Erhardt. In Drug Metabolism: Databases and High Throughput Testing During Drug Design and Development, ed. by P. Erhardt, IUPAC/Blackwell, Geneva, 1999.

  16. Case Studies: A Prodrug and a Softdrug. P. Erhardt. In Drug Metabolism: Databases and High Throughput Testing During Drug Design and Development, ed. by P. Erhardt, IUPAC/Blackwell, Geneva,1999.

  17. Prodrugs and Codrugs T. Wilbury (P. Erhardt et al.) In Drug Metabolism: Databases and High Throughput Testing During Drug Design and Development,ed. by P. Erhardt, IUPAC/Blackwell, Geneva, 1999.

  18. Statistics-Based Probabilities of Metabolic Possibilities. P. Erhardt. In Drug Metabolism: Databases and High Throughput Testing During Drug Design and Development, ed. by P. Erhardt, IUPAC/Blackwell, Geneva, 1999.

  19. Drug Metabolism: Databases and High Throughput Testing During Drug Design and Development. Served as organizer and editor for entire text which has over 50 international expert contributors. Published by IUPAC/Blackwell, Geneva, 1999.

  20. Z. Hu, M.J. Hardie, P. Burckel, A.A. Pinkerton and P.W. Erhardt Conversion of 2,4-Dihydroxybenzaldehyde to 2-Benzoyloxy-4-hydroxybenzaldehyde and their Structural Characterization. J. Chem. Crystallog., 29, 185-191, 1999.

  21. Methods For Producing Two-Substituted Glycerols Having Various Levels of Protection. P. Erhardt and W. Klis. U.S. Patent Application, Filed 2000.

  22. Aralkyl Ester Softdrugs. P. Erhardt. U.S. Patent Application, Filed 2000.

  23. AConvenient Synthesis of 2-Phenylglycerol. P. Erhardt and W. Klis. Synth. Comm., Accepted.

  24. 2-Phenylglycerol: Crystal Structure and Conformational Considerations Pertaining to Formation of Its Related Oxetane. P.W. Erhardt, W.A. Klis, P.I. Nagy, K. Kirschbaum, N. Wu, A. Martin and A.A. Pinkerton. J. Chem. Crystallog, accepted.

  25. Metabolism Prediction. P. Erhardt. Bio Techniques, Accepted. Reproducibility of the High-Performance Liquid Chromatographic Fingerprints Obtained From Two Soybean Cultivars and a Selected Progeny. J. Faghihi, X. Jiang, R. Vierling, S. Goldman, S. Sharfstein and P. Erhardt. J. Chrom. A submitted.
Last Updated: 4/17/19